Unknown

Dataset Information

0

Cost-Effectiveness of Pediatric Central Venous Catheters in the UK: A Secondary Publication from the CATCH Clinical Trial.


ABSTRACT: Background: Antibiotic-impregnated central venous catheters (CVCs) reduce the risk of bloodstream infections (BSIs) in patients treated in pediatric intensive care units (PICUs). However, it is unclear if they are cost-effective from the perspective of the National Health Service (NHS) in the UK. Methods: Economic evaluation alongside the CATCH trial (ISRCTN34884569) to estimate the incremental cost effectiveness ratio (ICER) of antibiotic-impregnated (rifampicin and minocycline), heparin-bonded and standard polyurethane CVCs. The 6-month costs of CVCs and hospital admissions and visits were determined from administrative hospital data and case report forms. Results: BSIs were detected in 3.59% (18/502) of patients randomized to standard, 1.44% (7/486) to antibiotic and 3.42% (17/497) to heparin CVCs. Lengths of hospital stay did not differ between intervention groups. Total mean costs (95% confidence interval) were: £45,663 (£41,647-£50,009) for antibiotic, £42,065 (£38,322-£46,110) for heparin, and £44,503 (£40,619-£48,666) for standard CVCs. As heparin CVCs were not clinically effective at reducing BSI rate compared to standard CVCs, they were considered not to be cost-effective. The ICER for antibiotic vs. standard CVCs, of £54,057 per BSI avoided, was sensitive to the analytical time horizon. Conclusions: Substituting standard CVCs for antibiotic CVCs in PICUs will result in reduced occurrence of BSI but there is uncertainty as to whether this would be a cost-effective strategy for the NHS.

SUBMITTER: Ridyard CH 

PROVIDER: S-EPMC5610787 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cost-Effectiveness of Pediatric Central Venous Catheters in the UK: A Secondary Publication from the CATCH Clinical Trial.

Ridyard Colin H CH   Plumpton Catrin O CO   Gilbert Ruth E RE   Hughes Dyfrig A DA  

Frontiers in pharmacology 20170919


<b>Background:</b> Antibiotic-impregnated central venous catheters (CVCs) reduce the risk of bloodstream infections (BSIs) in patients treated in pediatric intensive care units (PICUs). However, it is unclear if they are cost-effective from the perspective of the National Health Service (NHS) in the UK. <b>Methods:</b> Economic evaluation alongside the CATCH trial (ISRCTN34884569) to estimate the incremental cost effectiveness ratio (ICER) of antibiotic-impregnated (rifampicin and minocycline),  ...[more]

Similar Datasets

| S-EPMC4472776 | biostudies-literature
| S-EPMC6438638 | biostudies-literature
| S-EPMC5778275 | biostudies-literature
| S-EPMC7228048 | biostudies-literature
| S-EPMC6389340 | biostudies-literature
| S-EPMC2292495 | biostudies-other
| S-EPMC6302318 | biostudies-literature
| S-EPMC9124179 | biostudies-literature
| S-EPMC6994843 | biostudies-literature
| S-EPMC5010186 | biostudies-literature